Biocryst Pharmaceuticals

Filed a patent for "oral dosage forms and oral dosing regimens for treatment of complement mediated diseases" on Fri, January 6, 2023

Filed a patent for "oral dosage forms and oral dosing regimens for treatment of complement mediated diseases" on Thu, July 6, 2023

Filed a patent for "oral dosage forms and oral dosing regimens for treatment of complement mediated diseases" on Thu, November 2, 2023

Filed a patent for "substituted benzofuran, benzopyrrole, benzothiophene, and structurally relatedcomplement inhibitors" on Thu, September 5, 2024

Filed a patent for "fusion protein inhibitors of klk5" on Wed, July 20, 2022

Filed a patent for "methods, compositions, and dosing regimens for treatment of sars-cov-2 infections" on Thu, May 25, 2023

Filed a patent for "benzopyrazole compounds and analogues thereof" on Thu, July 13, 2023

Filed a patent for "synthesis of an antiviral azasugar triphosphate" on Thu, September 28, 2023

Filed a patent for "imidazole-containing inhibitors of alk2 kinase" on Thu, August 31, 2023

Filed a patent for "crystalline salts of a plasma kallikrein inhibitor" on Thu, April 4, 2024

Filed a patent for "human plasma kallikrein inhibitors" on Thu, May 9, 2024

Filed a patent for "human plasma kallikrein inhibitors" on Thu, May 9, 2024

Filed a patent for "dosing regimens for oral alk2 kinase inhibitors" on Wed, June 21, 2023

Filed a patent for "pyrrolopyrimidine amines as complement inhibitors" on Thu, May 25, 2023

Filed a patent for "methods of treating hematologic cancers" on Thu, March 28, 2024

Filed a patent for "substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors" on Thu, March 9, 2023

Filed a patent for "substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors" on Thu, March 30, 2023